| Drug ID: | Drug30 |
|---|---|
| Drug Name: | Mirtazapine |
| CID: | 4205 |
| DrugBank ID: | DB00370 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06309472 |
| Molecular Formula: | C17H19N3 |
| Molecular Weight: | 265.35 g/mol |
| Isomeric SMILES: | CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4 |
| Synonyms: | mirtazapine; 85650-52-8; 61337-67-5; Zispin; 6-Azamianserin; Mepirzepine; Remergil; Promyrtil; Remergon; Norset |
| Phase 0: | 4 |
| Phase 1: | 16 |
| Phase 2: | 31 |
| Phase 3: | 14 |
| Phase 4: | 34 |
| Description: | Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt278 | 4205 | Mirtazapine | 3356 | HTR2A | Homo sapiens (human) | None | |
| dt279 | 4205 | Mirtazapine | 3350 | HTR1A | Homo sapiens (human) | None | |
| dt280 | 4205 | Mirtazapine | 150 | ADRA2A | Homo sapiens (human) | None | |
| dt281 | 4205 | Mirtazapine | 3358 | HTR2C | Homo sapiens (human) | 15771415 | Antagonist |
| dt282 | 4205 | Mirtazapine | 51083 | GAL | Homo sapiens (human) | None | |
| dt283 | 4205 | Mirtazapine | 121278 | TPH2 | Homo sapiens (human) | None | |
| dt284 | 4205 | Mirtazapine | 25 | ABL1 | Homo sapiens (human) | Inhibitor | |
| dt285 | 4205 | Mirtazapine | 3358 | HTR2C | Homo sapiens (human) | Inhibitor | |
| dt286 | 4205 | Mirtazapine | 3358 | HTR2C | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06309472 | Trial of Mirtazapine for Depression in IBD | PHASE2 | RECRUITING | King's College London | Major Depressive Disorder|Inflammatory Bowel Dise… | DRUG: Mirtazapine|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations